FIELD: medicine. SUBSTANCE: essence of this method resides in comprehensively treating patient with thypontin to be administered subcutaneously in dose of 100 kg at interval of 4 to 5 days (cure: 4 to 5 injections, each measuring 400 to 500 mcg). EFFECT: higher clinical effectiveness, shorter treatment period, prevention of complications and relapses, less pronsedness of intoxication syndrome, and acceleration of reverse development of local manifestation of disease. 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING PATIENTS SUFFERING FROM COMPLICATED FORMS OF ERYSIPELAS | 2014 |
|
RU2546039C1 |
| METHOD OF TREATING ERYSIPELAS IN DIABETIC PATIENTS | 0 |
|
SU1806742A1 |
| METHOD OF TREATING PATIENTS WITH PYOINFLAMMATORY SKIN DISEASES | 2009 |
|
RU2423976C2 |
| AGENT FOR TREATMENT LIMBS ERYSIPELAS | 1995 |
|
RU2096039C1 |
| METHOD FOR ESTIMATING EFFECTIVENESS OF CORRECTION OF INFLAMMATORY PROCESS WITH UNDERLYING TREATMENT OF PATIENTS WITH BULLOUS ERYSIPELAS | 2007 |
|
RU2373541C2 |
| METHOD FOR TREATMENT OF THE ERYTHEMATIOUS FORM OF SACRED FIRE | 2016 |
|
RU2649963C1 |
| METHOD OF TREATMENT OF ERYSIPELAS | 0 |
|
SU1289461A1 |
| METHOD OF ERYSIPELATOUS INFLAMMATION TREATMENT | 0 |
|
SU1811846A1 |
| METHOD OF TREATMENT OF PATIENTS WITH ERYSIPELAS | 1995 |
|
RU2120286C1 |
| METHOD OF TREATMENT OF ERYTHEMATOUS-BULLOUS FORM OF ERYSIPELAS | 2023 |
|
RU2803130C1 |
